GlobeNewswire

Freenome Reports Third Quarter 2026 Financial Results
10/11/2026
– Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC – – Entered the public market and raised gross proceeds of $310 million – BRISBANE, Calif., Nov. 10, 2026 (GLOBE [...]
Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
10/11/2026
WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti- [...]
Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London
10/11/2026
Mechelen, Belgium; November 10, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 2026 Jefferies Global Healthcare Conference [...]
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
10/11/2026
– KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority share of new patient starts of the [...]
Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
10/11/2026
ST. LOUIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial [...]
Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers
10/11/2026
Recognition marks second consecutive year Amneal has been named a BioSpace Best Place to Work BRIDGEWATER, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) [...]
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
10/11/2026
52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LIONHEART-HCM oHCM [...]
Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance
10/11/2026
REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for [...]
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
10/11/2026
SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the genetics of the [...]
Glass House Brands to Host Third Quarter 2026 Earnings Call on November 16, 2026
10/11/2026
LONG BEACH, Calif. and TORONTO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (NYSE: GLAS), one of the fastest-growing cannabis companies in the U.S., [...]
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
10/11/2026
A majority-owned and controlled subsidiary of Fortress entered into an agreement with Cedars-Sinai to license FB-607, which is currently being evaluated in an ongoing Phase 2 study for IBS-D MIAMI, Nov. 10, 2026 (GLOBE [...]
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
10/11/2026
Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing S-4 Declared Effective by SEC; Stockholder Vote Scheduled for December 9, [...]
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
10/11/2026
Completed enrollment in the Phase II COVALENT-211 clinical trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes (“T2D”); topline data expected in the first quarter of 2027 Enrollment ongoing in [...]
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
10/11/2026
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
10/11/2026
FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A MGX-001 is designed to deliver durable, endogenous Factor VIII (FVIII) activity from a one-time treatment for [...]
Bionano Reports Third Quarter 2026 Results and Provides a Business Update
10/11/2026
Conference call today, November 10, 2026, at 4:30 PM ET SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2026 [...]
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
10/11/2026
Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 Major BLA amendment added two-year open-label extension (OLE) HOPE-3 [...]
PetMeds® Announces Second Quarter Financial Results
10/11/2026
DELRAY BEACH, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2026 [...]
Lumexa Imaging Announces Third Quarter 2026 Results
10/11/2026
RALEIGH, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the third quarter ended September 30, 2026 [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum